Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT
Date:7/10/2014

compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company utilized the services of paid stock promoters to inflate its share price; (ii) contrary to the Company's representations, preparations were not underway for a Phase 3 study for PV-10; and (iii) the Company improperly referred to PV-10 as obtaining a Breakthrough Therapy Designation ("BTD"), and otherwise implied that obtaining that status was inevitable.

On January 23, 2014, an article was published on TheStreet.com, accusing Provectus of artificially inflating the price of its stock by making false representations related to the commencement of Phase III clinical trials. 

On this news, the Company's shares declined $3.35, or over 64%, to close at $21.87 on January 23, 2014.

Prior to May 20, 2014, the Company's website improperly described its PV-10 drug as a "breakthrough" drug for skin cancer, prior to the FDA's designation of the drug as such.  On May 20, 2014, the Company updated its website and changed the description of PV-10 to "An Investigational Drug for Cancer" and included language clearly indicating that the drug was still awaiting BTD designation by the FDA.

On this news, Provectus securities declined $0.31 per share, or over 10%, to close at $2.70 per share on May 20, 2014.

On May 21, 2014, an article was published on SeekingAlpha.com alleging that the Company was tied to stock promoters that improperly marketed the Company's stock to unsophisticated retail investors, thus artificially inflating the price of the Company's shares.  The article noted that trading in many of the other companies associated with these stock promoters was recently halted by the SEC.  That same day, Provectus issued a press release refuting the allegations of the SeekingAlpha.com article.  Provectus specifically noted that PV-10, its investigational metasta
'/>"/>

SOURCE Pomerantz LLP
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Acquisition of BioClinica, Inc. by JLL Partners, Inc. May Not Be in BioClinica, Inc. Shareholders Best Interests
2. Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel
3. Investigation of American Oriental Bioengineering, Inc. by Securities Lawyers at Goldfarb LLP Law Firm for Potential Shareholder Claim
4. Red alert: Body kills spontaneous blood cancers on a daily basis
5. Media alert: Society of Interventional Radiologys Annual Scientific Meeting
6. Webcast alert: Molecular Medicine Institute to give new hope to pediatric patients
7. Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors
8. BrightFocus Foundation announces 55 new grantees in Alzheimers and vision research
9. Elsevier Announces the launch of open access journal: New Negatives in Plant Science
10. Institute of Physics announces 2014 award winners
11. Elsevier announces the launch of a new journal: Current Opinion in Behavioral Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Researchers from the University of Copenhagen have shown for ... the lungs of Cystic fibrosis patients, giving them the ... growth in chronic infections. , The study also discovered ... fibrosis (CF) patients was halted or slowed down by ... consumed all the oxygen and helped "suffocate" the bacteria, ...
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... Harvard Medical School and Massachusetts Institute of Technology (MIT), ... have shown for the first time that targeted drug ... acid ligands (referred to as aptamers) are short DNA ... with high specificity and affinity; analogous to monoclonal antibodies. ...
... of Energy's Argonne National Laboratory have found elevated amounts ... composer Ludwig von Beethoven, consistent with their earlier finding ... These results confirm the cause of his years of ... DNA testing to have come from Beethoven's body, were ...
... dog genome-related materials are published, including a new book entitled ... of primary research articles in the journal Genome Research ... Nature of a high-quality draft sequence of the dog ... with informative resources about canine genomics and biology. , "Canine ...
Cached Biology News:Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates 2Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates 3Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates 4Argonne researchers confirm lead in Beethoven's illness 2Argonne researchers confirm lead in Beethoven's illness 3Scientists fetch useful information from dog genome publications 2Scientists fetch useful information from dog genome publications 3Scientists fetch useful information from dog genome publications 4
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
(Date:10/20/2014)... VIENNA , October 20, 2014 ... of gastrointestinal (GI) disorders and the delivery of care ... liver diseases and worrying inequalities in the provision of ... survey, which was commissioned by United European Gastroenterology (UEG), ... greater political and public awareness of the burden of ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... ... than men when treated with minimally invasive endovascular therapy. Two years after endovascular treatment, ... study of 277 patients. , ... (PRWEB) January 18, 2010 -- Women who are at risk of lower-leg amputation fare ...
... global sources of protein and oil, is now the ... sequence. The sequence and its analysis appear in ... . The research team comprised 18 institutions, including ... JGI), the U.S. Department of Agriculture-Agricultural Research Service (USDA-ARS), ...
... AUSTIN, Texas, Jan. 7 Bender Consulting, a premier boutique ... merger and acquisition (M&A) related activity that will have the ... Bender Consulting combines proven industry experts and world-class consulting resources ... Bio Tech clients. The talent at Bender Consulting has been ...
Cached Biology Technology:Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 2Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 3Soybean genome analysis reveals pathways for improving biodiesel 2Soybean genome analysis reveals pathways for improving biodiesel 3Bender Consulting Predicts Key Trends and Merger and Acquisition Activity for the Oil & Gas Sector in 2010 2Bender Consulting Predicts Key Trends and Merger and Acquisition Activity for the Oil & Gas Sector in 2010 3
...
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... Tetrad 2 thermal cycler is a completely ... Tetrad chassis, and it accepts the full ... delivers the same precision in thermal performance ... Tetrad thermal cyclers, allowing easy transport of ...
... includes 2 tube gel adaptors, 24 ... length), gaskets, grommets, stoppers. The PROTEAN II ... cell offer the versatility to perform a ... second-dimension 2-D electrophoresis, native, preparative, and gradient ...
Biology Products: